OCTIMET ONCOLOGY
OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.
OCTIMET ONCOLOGY
Industry:
Biotechnology Medical
Founded:
2016-01-01
Address:
Beerse, Antwerpen, Belgium
Country:
Belgium
Website Url:
http://www.octimet.com
Total Employee:
11+
Status:
Active
Contact:
+32473558353
Email Addresses:
[email protected]
Total Funding:
12.38 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Nginx Microsoft Exchange Online
Similar Organizations
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Oxford Cannabinoid Technologies
OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO) investment in Grant - OCTIMET Oncology
Fund+
Fund+ investment in Series A - OCTIMET Oncology
V-Bio Ventures
V-Bio Ventures investment in Series A - OCTIMET Oncology
Omnes Capital
Omnes Capital investment in Series A - OCTIMET Oncology
Droia Ventures
Droia Ventures investment in Series A - OCTIMET Oncology
Official Site Inspections
http://www.octimet.com
- Host name: linweb122.webhosting.be
- IP address: 185.162.30.91
- Location: Brussels Belgium
- Latitude: 50.8336
- Longitude: 4.3337
- Timezone: Europe/Brussels
- Postal: 1060
More informations about "OCTIMET Oncology"
OCTIMET
OCTIMET have now partnered OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China and DeuterOncology NV for Rest of the World. OMO-1 is an oral, highly selective small molecule MET kinase …See details»
OCTIMET Oncology - Crunchbase Company Profile & Funding
Organization. OCTIMET Oncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... OCTIMET oncology’s overall strategy is …See details»
OCTIMET Oncology NV: Contact Details and Business Profile
OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen. Headed by Dr. Timothy Perera (CEO), OCTIMET has …See details»
OCTIMET Oncology - Overview, News & Similar companies
Who is OCTIMET Oncology. OCTIMET Oncology NV acts as a translational accelerator, focusing on creating value for patients and investors by providing rapid clinical proof of concept for …See details»
OCTIMET Oncology - Org Chart, Teams, Culture & Jobs - The Org
View OCTIMET Oncology's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
OCTIMET Oncology NV - Drug pipelines, Patents, Clinical trials
Explore OCTIMET Oncology NV with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Neoplasms, Technology Platform:Small molecule drug, …See details»
OCTIMET Oncology NV - LinkedIn
OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen. Headed by Dr. Timothy Perera (CEO), OCTIMET has …See details»
OCTIMET Oncology Company Profile - Office Locations ... - Craft
OCTIMET Oncology has 5 employees across 2 locations and $13.41 m in total funding,. See insights on OCTIMET Oncology including office locations, competitors, revenue, financials, …See details»
OCTIMET Oncology - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Aug 8, 2018 ... Agentschap …See details»
OCTIMET Oncology - Crunchbase
OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profilesSee details»
OCTIMET Oncology NV | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Octimet Oncology - VentureRadar
OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing …See details»
Octimet Oncology - PitchBook
Octimet Oncology General Information Description. Developer of discovery-stage molecules designed to treat cancer cells. The company's molecules include cMET inhibitor and other …See details»
OCTIMET Oncology - Products, Competitors, Financials, Employees ...
OCTIMET Oncology is a biopharmaceutical company focused on the development of highly selective small molecule MET kinase inhibitors for cancer treatment. The company's main …See details»
OCTIMET Oncology announces Shelley Margetson as CEO - LinkedIn
Jun 4, 2019 Telephone: +31 (0) 631 900 812 - E-Mail: [email protected] www.octimet.com Help improve contributions Mark contributions as unhelpful if you find them …See details»
Octimet bags €11m for development of cancer drugs
Jan 19, 2017 Octimet s current pipeline relies on several selective MET (Mesenchymal-eptihelial Transition Factor) kinase inhibitors, licensed from Janssen Pharmaceutica NV. The company, …See details»
OCTIMET Oncology - Contacts, Employees, Board Members
Organization. OCTIMET Oncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Contacts 1. About. OCTIMET Oncology has 3 current …See details»
OCTIMET Oncology - EU-Startups
OCTIMET have now partnered OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China and DeuterOncology NV for Rest of the World. OMO-1 is an oral, highly …See details»
Deuteroncology – Next generation of MET kinase inhibitor
The molecule was in-licensed (worldwide rights) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017. Key Facts About Us. Next generation of MET …See details»
ATime
Online casino 5 dollar minimum deposit in Australia. Welcome Bonus. You can make deposits is a Minimum Deposit Casinos. Tips to Get the Most of any amounts free of other factors of any …See details»